Artemether
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]-2-benzopyran | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Pregnancy cat. |
|
Legal status | |
Routes | Oral |
Identifiers | |
CAS number | 71963-77-4 |
ATC code | P01BE02 |
PubChem | CID 68911 |
DrugBank | DB06697 |
ChemSpider | 62138 |
UNII | C7D6T3H22J |
KEGG | D02483 |
ChEBI | CHEBI:195280 |
ChEMBL | CHEMBL1237051 |
Chemical data | |
Formula | C16H26O5 |
Mol. mass | 298.374 g/mol |
(what is this?) (verify) |
Artemether (INN) is an antimalarial for the treatment of multiple drug-resistant strains of Plasmodium falciparum malaria. Its combination (coformulation) withLumefantrine has first been marketed by Novartis under the brand names Riamet and Coartem. Today, this combination therapy is available as generic from several manufacturers.
It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.[1]